Filing Details
- Accession Number:
- 0000914475-13-000053
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-07-16 17:49:53
- Reporting Period:
- 2013-07-12
- Filing Date:
- 2013-07-16
- Accepted Time:
- 2013-07-16 17:49:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1343124 | Flint Christopher Obrien | Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego CA 92130 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2013-07-12 | 5,000 | $14.50 | 94,794 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Nonstatutory Stock Option | Acquisiton | 2013-07-12 | 5,000 | $5.12 | 5,000 | $5.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,000 | 2009-02-27 | 2015-02-27 | No | 4 | X | Direct |
Footnotes
- Exercise of in-the-money or at-the-money derivative security
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.